Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, v-rel reticuloendotheliosis viral oncogene homolog B (RelB).

这一计划与国家研究重点：促进和保持良好健康相一致。致残性疾病类风湿性关节炎和1型糖尿病影响着澳大利亚超过1%的人口。它们是不治之症，因此残疾和治疗需求持续到老年，预期寿命减少。该计划的重点是通过免疫疗法进行更有效、更安全的治疗，以及未来的疾病预防。这将给澳大利亚带来社会效益和经济效益。这项研究将促进澳大利亚在免疫学方面的学术领先地位，提供研究培训和职业机会，并将促进基础科学家、临床医生和业界之间的密切合作。

This program is well-aligned with the national research priority: Promoting and Maintaining Good Health. The disabling conditions rheumatoid arthritis and type 1 diabetes affect over 1% of Australia's population. They are incurable, so disability and the need for treatment persist into old age and life expectancy is reduced. The program focuses on more effective and safer treatment, and future disease prevention, with immune therapy. This will have social and economic benefits to Australia. The research will advance Australia's intellectual leadership in Immunology, providing research training and career opportunities, and will lead to strong collaborations between basic scientists, clinicians and industry.